KAREN BROWN: Open Payments
NPI 1558342956 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,873 in 89 payments from 18 companies in 2025. Trend: 2023 $1,267 · 2024 $1,708 · 2025 $1,873
Food & beverage: $1,854Education: $19
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $280 |
| ABBVIE INC. | 14 | $246 |
| Otsuka America Pharmaceutical, Inc. | 11 | $202 |
| Teva Pharmaceuticals USA, Inc. | 10 | $190 |
| Neurocrine BioSciences, Inc. | 7 | $178 |
| Corium, LLC | 5 | $147 |
| Alkermes, Inc. | 5 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| Vanda Pharmaceuticals Inc. | 3 | $61 |
Products named: CAPLYTA, REXULTI, INGREZZA, VRAYLAR, AUSTEDO XR, Azstarys, ARISTADA, DURYSTA.
Industry payments across TX — which companies pay providers there.
